Current Report Filing (8-k)
December 03 2014 - 9:44AM
Edgar (US Regulatory)
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities and Exchange Act of 1934
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
December 1, 2014
NANOVIRICIDES, INC.
(Exact Name of Registrant as Specified in
its Charter)
Nevada |
|
001-36081 |
|
76-0674577 |
(State of Organization) |
|
(Commission File Number) |
|
(I.R.S. Employer |
|
|
|
|
Identification No.) |
135 Wood Street, Suite 205, West Haven,
CT 06516
(Address of principal executive offices)
Registrant’s telephone number, including
area code: (203) 937-6137
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Merger Act (17 CFR 240.14a -12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Merger Act (17 CFR 240.14d -2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Merger Act (17 CFR 240.13e -4(c))
ITEM 4.01. CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT.
(a) Dismissal of Independent Registered
Public Accounting Firm
On December 1, 2014, Li and Company, PC
(“Li”) was dismissed as the independent registered public accounting firm of NanoViricides, Inc. (the “Company”).
The Company’s Board of Directors and audit committee approved the dismissal of Li.
Li’s reports on the Company’s
financial statements for the years ended June 30, 2014 and 2013, respectively, did not contain any adverse opinion or disclaimer
of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles.
During the years ended June 30, 2014 and
2013, and through December 1, 2014, there were no disagreements with Li on any matter of accounting principles or practices, financial
statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Li, would have
caused it to make reference thereto in connection with its reports on the financial statements for such years. During the years
ended June 30, 2014 and 2013, and through December 2, 2014, there were no matters that were either the subject of a disagreement
as defined in Item 304(a)(1)(iv) of Regulation S-K or a reportable event as described in Item 304(a)(1)(v) of Regulation S-K.
The Company provided Li with a copy of
the foregoing disclosures and requested Li to furnish the Company with a letter addressed to the Securities and Exchange Commission
stating whether or not Li agrees with the disclosures. A copy of Li’s letter is filed as Exhibit 16.1 to this Current Report
on Form 8-K.
(b) New Independent Registered Public Accounting Firm
On December 2, 2014, the Company’s
Board of Directors, acting in the capacity of an audit committee, engaged Eisner Amper LLP (“Eisner”) as the Company’s
new independent registered public accounting firm to act as the principal accountant to audit the Company’s financial statements.
During the Company’s fiscal years ended June 30, 2014 and 2013, and through December 2, 2014, neither the Company, nor anyone
acting on its behalf, consulted with Eisner regarding the application of accounting principles to a specific completed or proposed
transaction or the type of audit opinion that might be rendered on the Company’s financial statements, and no written report
or oral advice was provided that Eisner concluded was an important factor considered by the Company in reaching a decision as to
any such accounting, auditing or financial reporting issue.
Item 9.01. Financial Statements and Exhibits.
Exhibit
No. |
|
Description |
|
|
|
16.1 |
|
Letter to the Securities and Exchange Commission from Li and
Company, PC regarding the matters disclosed in Item 4.01 of this Current Report on Form 8-K. |
SIGNATURES
Pursuant to the requirements of the Securities
and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Date: December 3, 2014 |
NANOVIRICIDES, INC. |
|
|
|
|
|
|
|
By: |
/s/ Meeta Vyas |
|
|
Name: Meeta Vyas |
|
|
Title: Chief Financial Officer |
EXHIBIT 16.1
December 2, 2014
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549
We have read the statements of NanoViricides,
Inc. pertaining to our firm included under Item 4.01 of Form 8-K dated December 1, 2014 and agree with such statements as they
pertain to our firm.
Sincerely,
/s/ Li and Company, PC
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Sep 2024 to Oct 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Oct 2023 to Oct 2024